Tumor Biology

, Volume 31, Issue 2, pp 113–119 | Cite as

HE4: a new potential early biomarker for the recurrence of ovarian cancer

  • Emanuela AnastasiEmail author
  • Giulia Giovanna Marchei
  • Valentina Viggiani
  • Giuseppina Gennarini
  • Luigi Frati
  • Maria Gabriella Reale
Research Article


Human epididymis protein 4 (HE4) has recently been described as a new marker for the early diagnosis of ovarian cancer (OC). The objective of this study was to evaluate (a) the expression of HE4 vs. OC mucin CA125 in 32 patients with OC compared to 163 patients with other malignant or benign pathologies (b) HE4 as indicator of the recurrence of the disease in eight patients followed-up for 20 months after OC diagnosis. Serum HE4 and CA 125 levels were determined by ELISA and IRMA, respectively. At diagnosis, the patients with OC demonstrated high levels of both biomarkers with 96.9% sensitivity for HE4 and 85.7% for CA125. In the other pathologies there was 3.7% positivity for HE4 and 21.0% for CA125. The follow-up study showed an increase of HE4 5–8 months before CA125 increment in five of the eight patients, this early expression being strictly associated to a relapse of the disease. In conclusion, this study showed that HE4, compared to CA125, potentially is a better marker for the diagnosis of OC and could be an important early indicator of the recurrence of the disease.


Ovarian cancer Biomarkers HE4 CA125 



This study is founded by The University of Rome “Sapienza”. We are thankful to Barbara Colaprisca and Silvestra Tudini for their technical assistance, to Prof. Mauizio Sensi, Prof. Susanna Morano and Claudio Tiberti for helpful comments and discussion, and Prof. Bruno Annibale for his contribution to the statistical work.

Conflict of interest statement



  1. 1.
    Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002;20:1161–3.PubMedGoogle Scholar
  2. 2.
    Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827–41.CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Haries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 2002;3:529–36.CrossRefGoogle Scholar
  5. 5.
    Pecorelli S, Creasman WT, Petterson F, Benedet JL, Shepard JH. FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat. 1988;3:75–102.Google Scholar
  6. 6.
    Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99:267–77.CrossRefPubMedGoogle Scholar
  7. 7.
    Bast Jr RC, Badgwell D, Marquez LR, Rosen D, Liu J, Baggerly KA, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15:274–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic mass. Obstet Gynecol. 1988;72:23–7.PubMedGoogle Scholar
  9. 9.
    Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009;142:99–05.PubMedGoogle Scholar
  10. 10.
    Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer. 2009;115:1395–403.CrossRefPubMedGoogle Scholar
  11. 11.
    Urban N, McIntosh M, Andersen M, Karlan B. Ovarian cancer screening. Hematol Oncol Clin North Am. 2003;17:989–05.CrossRefPubMedGoogle Scholar
  12. 12.
    Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod. 1998;3:86–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Bingle L, Singleton V, Bingle CD. The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Clauss A, Lilja H, Lundwall A. The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun. 2005;333:383–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acid protein. Biochem J. 2002;368:233–42.CrossRefPubMedGoogle Scholar
  16. 16.
    Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.CrossRefPubMedGoogle Scholar
  17. 17.
    McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004;95:9–15.CrossRefPubMedGoogle Scholar
  18. 18.
    Galgano MT, Hampton GM, Frierson Jr HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–53.PubMedGoogle Scholar
  19. 19.
    Moore RG, Brown AK, Miller MC, Kates S, Allard WJ, Verch MS, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Allard J, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrial adenocarcinoma of the uterus. Gynecol Oncol. 2008;108:196–201.CrossRefGoogle Scholar
  21. 21.
    Schink JC. Current initial therapy of stage II and IV ovarian cancer: challenges for managed care. Sem Oncol. 1999;26:2–7.Google Scholar
  22. 22.
    Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal risk factors for ovarian. Am J Epidemiol. 2008;167:1059–69.CrossRefPubMedGoogle Scholar
  23. 23.
    Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Tuxen TGC, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15:679–91.CrossRefPubMedGoogle Scholar
  24. 24.
    Hellerstrom I, Hellerstron KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol. 2008;622:15–21.CrossRefGoogle Scholar
  25. 25.
    Allard J, Somers E, Theil R, Moore RG. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer. Annual meeting of the ASCO 2008 Abstract.Google Scholar
  26. 26.
    Carroll JC, Cremin C, Allanson J, Blaine SM, Dorman H, Gibbons CA, et al. Hereditary breast and ovarian cancers. Can Fam Physician. 2008;54:1691–2. Review.PubMedGoogle Scholar
  27. 27.
    Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, et al. Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol. 2009;3:171–81.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Emanuela Anastasi
    • 1
    Email author
  • Giulia Giovanna Marchei
    • 1
  • Valentina Viggiani
    • 1
  • Giuseppina Gennarini
    • 1
  • Luigi Frati
    • 1
  • Maria Gabriella Reale
    • 1
  1. 1.Department of OncologyUniversity “Sapienza”RomeItaly

Personalised recommendations